While oral probiotics show promise in treating inflammatory bowel disease, the primary
challenge lies in sustaining their activity and retention within the inflamed gastrointestinal …

Despite the great progress of current bacterially based biotherapeutics, their unsatisfying
efficacy and underlying safety problems have limited their clinical application. Herein …

Acute colitis is characterized by the microenvironment with a high level of inflammation,
oxidative stress as well as a disordered microbiome. Sustained delivery of the therapeutic …

Manipulation of the gut microbiota using oral microecological preparations has shown great
promise in treating various inflammatory disorders. However, delivering these preparations …

Inflammatory bowel disease (IBD) is closely associated with dysregulated immune
response, gut mucosal barrier, and microbiota. Conventional treatments suffer from inferior …

Inflammatory bowel disease (IBD) is a type of chronic recurrent inflammation disease that
mainly includes Crohn's disease and ulcerative colitis. Currently, the treatments for IBD …

Oral administration of probiotics is a promising method to alleviate inflammatory bowel
diseases (IBDs). However, gastrointestinal environmental sensitivity and inferior intestinal …

Inflammatory bowel disease (IBD) is a group of disabling, destructive and incurable immune-
mediated inflammatory diseases comprising Crohn's disease (CD) and ulcerative colitis …

Inflammatory bowel disease (IBD) is inflammatory intestinal disorders associated with
dysregulated gut microbiota. Bacteriotherapy that leverages bacteria as therapeutics has …

Microbiota‐based therapeutics offer innovative strategies to treat inflammatory bowel
diseases (IBDs). However, the poor clinical outcome so far and the limited flexibility of the …